Pair Name	Lupeol, Enzalutamide
Disease Info	[ICD-11: 2C82.0]	Prostate cancer		Investigative
Gene Regulation	Down-regulation	Expression	PTEN	hsa5728
	Down-regulation	Expression	MYC	hsa4609
	Down-regulation	Expression	CFLAR	hsa8837
	Down-regulation	Expression	HNF4A	hsa3172
In Vitro Model	PNT2	Healthy	Homo sapiens (Human)	CVCL_2164
	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
	PTEN-CaP8	Carcinoma of the mouse prostate gland	Mus musculus (Mouse)	CVCL_0F37
In Vivo Model	1×10⁶ PTEN-CaP8 cells were introduced subcutaneously in the right flanks of mice.
Result	Lupeol enhances the pharmacological efficacy of Enzalutamide and reduces the adverse effects. Thus, Lupeol could be a promising adjuvant for improving Enzalutamide-based treatment outcomes and warrant further research.